2024-05-29 14:45:14 ET
Summary
- Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets.
- There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights.
- I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.
Late last week, Wells Fargo put out a large list of potential and logical buyout targets in the biotech sector. They focused on the midcap space for various reasons. One of the names on the report was Viking Therapeutics, Inc. ( VKTX ) , which is on my short list of likely biotech acquisitions as well. However, I recently covered this mid-cap GLP-1 concern in this article , and I haven't been alone ( I , II ) here on Seeking Alpha in reaching that conclusion....
Read the full article on Seeking Alpha
For further details see:
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List